Metabolic dysfunction-associated steatotic liver disease (MASLD) has been the term for non-alcoholic fatty liver disease (NAFLD) since June 2023 and will be used instead of NAFLD throughout this review. MASLD currently represents the most common liver disease worldwide having a global estimated prevalence of 32 % [95 % confidence interval (CI):30–35 %] and a leading cause of liver-related morbidity and mortality [1,2]. MASLD prevalence differs significantly by world region attributed to disparities in obesity rates, genetic and socioeconomic influences.
